-- Zhejiang Medicine (SHA:600216) plans to spin off its subsidiary, Xinma Biopharmaceutical, for listing on the Hong Kong Stock Exchange, according to a Shanghai bourse filing on Saturday.
The Chinese drugmaker's shares dropped less than 4% on Monday.